Physician profile
Parker Hoffman
NPI 1831657642
$1,138.10
in general payments reported to CMS, 2019-2025
30 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $118 · 2023: $429 · 2024: $208 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $155.77 | 2022-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Pfizer INC. | $94.43 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $88.64 | 2023-2024 | |
| Edwards Lifesciences Corporation | $80.75 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $75.15 | 2025 | |
| Shockwave Medical, INC | $71.48 | 2025 | |
| Kerecis Limited | $66.51 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Smith+Nephew, INC. | $57.49 | 2023 | Pico, Renasys Go V2 Home |
| Lemaitre Vascular, INC. | $38.55 | 2022-2023 | Artegraft Vascular Graft |
| Kiniksa Pharmaceuticals International, Plc | $33.00 | 2024 | Arcalyst |
| Organogenesis INC. | $32.17 | 2021-2023 | Puraply |
| Kiniksa Pharmaceuticals, LTD. | $31.97 | 2022-2023 | Arcalyst |
| Boston Scientific Corporation | $26.12 | 2022-2025 | Enroute Transcarotid Neuroprotection System |
| Bridgebio Pharma, INC. | $23.11 | 2025 | Attruby |
| Scpharmaceuticals INC. | $22.08 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $19.43 | 2021 | |
| W. L. Gore & Associates, INC. | $18.59 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Sanofi-Aventis U.S. LLC | $17.83 | 2023 | |
| Amarin Pharma, INC. | $16.95 | 2021 | |
| La Jolla Pharmaceutical Company | $16.83 | 2021 | |
| Integra Lifesciences Corporation | $16.58 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Actelion Pharmaceuticals US, INC. | $16.43 | 2023 | Opsumit, Uptravi |
| Novo Nordisk INC | $15.86 | 2024 | Ozempic |
| Cvrx, INC. | $15.45 | 2025 | Barostim Neo System |
| Amgen INC. | $15.04 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $14.47 | 2023 | Verquvo |
| Terumo Medical Corporation | $14.39 | 2024 | Heartrail |
| Lexicon Pharmaceuticals, INC. | $14.39 | 2023 | Inpefa |
| Azurity Pharmaceuticals, INC. | $14.35 | 2024 | Edarbi |
| E.R. Squibb & Sons, L.L.C. | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parker Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.